
Cassava Sciences Inc (NASDAQ:SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam.
Among the latest concerns highlighted in the NYT article include a report that on March 30, the scientific journal PLoS One retracted five papers authored by Dr. H.Y. Wang, a Cassava (SAVA) adviser.